Policy & Regulation
Obsidian Therapeutics advances Agni-01 study with first patient enrolled in registration-enabling cohort
5 August 2026 - Clinical-stage biopharmaceutical company Obsidian Therapeutics Inc (Nasdaq:OBX) on Wednesday announced enrolment of the first patient in the registration-enabling cohort of its Phase 1...
Summit Therapeutics expands ivonescimab programme into bladder cancer with Phase II/III trial
5 August 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ: SMMT) reported on Wednesday that it has expanded the global clinical development programme for its investigational b...
Phylo partners with Chugai to advance AI agents in drug discovery
5 August 2026 - Phylo Inc, an applied AI research lab focused on agentic biology, announced on Tuesday a collaboration with Japan-based Chugai Pharmaceutical Co Ltd to deploy Biomni Lab, Phylo's ...
Lilly secures FDA Breakthrough Therapy designation for olomorasib in pancreatic cancer
3 August 2026 - Medicine company Eli Lilly and Company (NYSE: LLY) announced on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation for olomorasib as a monot...
Acurx receives FDA guidance supporting ibezapolstat Phase 3 development strategy
3 August 2026 - Biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ: ACXP) reported on Monday that it has received further FDA guidance on its ibezapolstat clinical development programme, incl...
Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation
3 August 2026 - Gene therapy company Genprex Inc (NASDAQ: GNPX) disclosed on Monday that it has entered into a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-...